Shantanu Kumar Singh

Executive Director & CFO
Taj Pharma Group

At Taj Pharma, our journey has always been guided by a simple yet powerful belief—quality healthcare must be accessible, affordable, and ethically delivered to every patient, everywhere.

As the Executive Director of Taj Pharma Group, I have had the privilege of witnessing the company evolve from a strong domestic manufacturer into a globally trusted pharmaceutical partner serving patients across more than 40 countries. This transformation has been driven not merely by expansion, but by an unwavering commitment to science, compliance, and public health responsibility.


Building a Globally Trusted Pharmaceutical Institution

In an increasingly complex and regulated global healthcare environment, pharmaceutical excellence today demands far more than manufacturing capability. It requires regulatory foresight, scientific integrity, financial discipline, and global collaboration.

At Taj Pharma, we have consciously invested in building:

  • Robust WHO-GMP and PIC/S-aligned manufacturing systems
  • Strong global regulatory and pharmacovigilance frameworks
  • Scalable international supply chains capable of serving both institutional and retail markets
  • A diversified portfolio across anti-infectives, oncology, chronic care, and specialty therapeutics

Our focus has been on long-term credibility rather than short-term gains—ensuring that every product bearing the Taj Pharma name meets the highest standards of quality, safety, and efficacy.


Leadership Philosophy

My leadership philosophy is anchored in three core principles:

Integrity in Action – Ethical decision-making and transparent governance are non-negotiable.
Science-Led Growth – Sustainable expansion must be rooted in research, data, and regulatory science.
Access with Accountability – Expanding access to medicines carries a responsibility to patients, governments, and global health systems.

Having worked across investment banking, pharmaceutical strategy, regulatory affairs, and international business, I firmly believe that successful pharmaceutical organizations are those that balance commercial strength with social responsibility.


Global Partnerships and Public Health Commitment

Over the past decade, Taj Pharma has built enduring partnerships with:

  • Ministries of Health
  • UN and multilateral procurement agencies
  • Global NGOs and institutional buyers
  • International pharmaceutical companies through licensing and contract manufacturing models

These collaborations have enabled us to deliver essential medicines during both routine supply cycles and global health emergencies, reinforcing our role as a reliable and responsible global supplier.


Innovation, Research & the Future

Innovation at Taj Pharma extends beyond products—it encompasses processes, systems, and mindset. We continue to invest in:

  • Advanced formulations and complex generics
  • Oncology injectables, hormonal therapies, and niche therapeutic segments
  • Digital transformation and Pharma 4.0 practices
  • Strengthened pharmacovigilance and post-marketing surveillance systems

Personally, my continued engagement in clinical and translational research, particularly in immunology and inflammation sciences, reinforces my belief that the future of pharmaceuticals lies at the intersection of research, regulation, and real-world patient impact.


Looking Ahead

As we look to the future, Taj Pharma remains focused on:

  • Expanding our direct presence in Latin America, Africa, and regulated markets
  • Driving technology transfer and international joint ventures
  • Strengthening biologics and biosimilars pathways
  • Supporting public–private partnerships that enhance healthcare access in emerging economies

Our aspiration is clear—to position Taj Pharma as a globally respected pharmaceutical institution, trusted by regulators, partners, and patients alike.


A Commitment Beyond Business

Pharmaceuticals is not just an industry—it is a responsibility. Every tablet, vial, or injectable we produce represents a patient who trusts us with their health and their future.

At Taj Pharma, we honour that trust every day.

I thank our employees, partners, regulators, and stakeholders for being an integral part of our journey. Together, we will continue to build an organization that not only grows globally—but serves humanity meaningfully.

At Taj Pharma Group, we view sustainable growth as the outcome of strategic clarity, regulatory discipline, and capital efficiency. In a global pharmaceutical landscape defined by tightening regulations, pricing pressures, and supply-chain volatility, our objective remains consistent: to build a resilient, scalable, and globally credible pharmaceutical enterprise.


Strategic Positioning

Taj Pharma has evolved into a diversified pharmaceutical platform with:

  • WHO-GMP and PIC/S aligned manufacturing infrastructure
  • A growing portfolio of complex generics, oncology, injectables, and specialty formulations
  • An established export footprint across 40+ international markets
  • Deep experience in institutional, government, and tender-based procurement models

This positioning allows us to balance volume-driven emerging markets with value-driven semi-regulated and regulated markets, thereby mitigating geographic and pricing risk.


Financial Discipline & Capital Allocation

As Executive Director & CFO, my focus has been on aligning growth with financial prudence and governance excellence. Key priorities include:

  • Disciplined capital deployment toward high-return therapeutic segments
  • Investment in regulatory assets that generate long-term annuity revenues
  • Strong working capital controls across exports and institutional business
  • Conservative leverage strategy with focus on cash-flow sustainability

Our expansion model emphasizes asset-light partnerships, CMOs, licensing, and joint ventures, allowing us to scale internationally without disproportionate balance-sheet stress.


Regulatory Assets as Value Drivers

In pharmaceuticals, regulatory approvals are not costs—they are strategic assets.

Taj Pharma continues to invest in:

  • Multi-country dossier development
  • Compliance with evolving WHO, PIC/S, and EU-aligned standards
  • Strengthened pharmacovigilance and quality risk management systems

These capabilities enable faster market access, improved tender competitiveness, and higher partner confidence—directly enhancing enterprise value.


Growth Levers

Our medium- to long-term growth strategy is anchored in five key levers:

  1. International Market Deepening
    Focused expansion in Africa, Latin America, GCC, and selective regulated markets.
  2. Complex & Specialty Portfolio Expansion
    Oncology, hormonal therapies, lyophilized injectables, and orphan segments.
  3. Institutional & Government Business
    Long-term supply agreements with Ministries of Health, UN agencies, and NGOs.
  4. Strategic Partnerships & JVs
    Technology transfer, local manufacturing alliances, and co-development models.
  5. Digital & Operational Excellence
    Pharma 4.0 initiatives improving visibility, compliance, and execution speed.

Risk Management & Governance

Risk management is embedded into Taj Pharma’s operating model. Our governance framework emphasizes:

  • Regulatory compliance across jurisdictions
  • Currency and geopolitical risk diversification
  • Strong legal and IP oversight
  • Transparent reporting and audit-ready systems

This approach has enabled us to operate successfully in high-complexity markets while maintaining operational continuity and stakeholder trust.


Long-Term Vision

Our long-term ambition is to position Taj Pharma as a globally relevant, mid-size pharmaceutical platform—capable of:

  • Consistent export-led growth
  • Strategic value creation through regulatory and therapeutic specialization
  • Participation in future biologics and biosimilars ecosystems
  • Delivering predictable returns while serving critical public health needs

We believe that responsible pharmaceutical businesses create durable value—for investors, regulators, partners, and patients alike.


Closing Perspective

Taj Pharma’s journey is one of measured growth, disciplined execution, and long-term vision. We remain committed to strengthening our fundamentals while selectively pursuing opportunities that enhance shareholder value.

I thank our investors, partners, and stakeholders for their continued confidence. Together, we are building a pharmaceutical organization designed not just for scale—but for sustainability, credibility, and enduring value creation.

Overview & Strategic Context

In an era marked by increased global healthcare demand, complex regulatory environments, and heightened expectations for quality and compliance, Taj Pharma India Ltd. stands as a robust, export-oriented pharmaceutical manufacturer committed to delivering safe, high-quality, and affordable medicines worldwide. Our manufacturing base, situated in Sarigam GIDC, Gujarat, India, houses state-of-the-art facilities certified by WHO-GMP, ISO 9001:2018, GLP, and PICS, with EU-GMP certification underway—a testament to our unwavering focus on global regulatory compliance and quality excellence.


Operational Scale & Capabilities

Our fully integrated facility has capacity to produce diversified formulations at scale, including:

  • 120 million tablets/month
  • 40 million capsules/month
  • 36,000 kg dry blended powders
  • 20 million effervescent tablets
  • 60 million oral jelly units
  • 40 million creams/ointments
  • 3 million oral sachets
    This broad capacity positions Taj Pharma as a preferred partner for global export markets, third-party manufacturing, and contract / private label solutions.

Quality & Compliance as Strategic Assets

In a competitive international landscape, regulatory compliance is not only a requirement—it is a strategic differentiator. Our facilities adhere to rigorous standards, meeting international pharmacopeia specifications (IP, BP, USP), and incorporating advanced QA/QC systems with dedicated analytical and microbiology labs that ensure batch-to-batch consistency, safety, and efficacy.


Portfolio & Global Market Reach

With a diversified product portfolio across broad therapeutic categories—and significant strengths in formulations such as antiretrovirals, cardiovasculars, CNS agents, and more—Taj Pharma is uniquely positioned to fulfill both retail and institutional demands in Africa, LATAM, Middle East, Southeast Asia, and CIS regions. We continue to build compliance-ready dossiers for emerging and semi-regulated markets, strengthening long-term demand pipelines.


Growth Strategy & Value Creation

Our strategic priorities align with long-term shareholder value creation:

  • Regulatory expansion: Securing EU-GMP and advanced dossier approvals to unlock regulated market entry.
  • Operational excellence: Integrating Pharma 4.0 practices to enhance traceability, compliance, and responsiveness.
  • Global partnerships: Building deeper ties with Ministries of Health, UN agencies, tender partners, and institutional buyers.
  • Portfolio diversification: Augmenting specialty and complex generics, including niche and high-barrier therapeutic segments.

These pipelines are designed to generate sustainable revenue streams while diversifying risk across regions and product classes.


Financial Discipline & Risk Management

Our financial strategy emphasizes capital efficiency, working capital discipline, and judicious investment in regulatory assets that generate recurring export income. We balance growth with prudent risk management, ensuring operational continuity amid geopolitical, currency, and supply chain fluctuations.


Commitment to Stakeholders

Taj Pharma’s ethos is rooted in delivering value to investors, partners, patients, and healthcare systems alike. We seek responsible growth that enhances shareholder confidence, strengthens healthcare access globally, and upholds the highest standards of corporate governance.


Closing Perspective

As we progress into the next financial year, Taj Pharma remains committed to scaling responsibly, deepening regulatory footprints, and enhancing global market access—all while strengthening our role as a credible, quality-focused pharmaceutical exporter from India. Thank you for your trust, partnership, and shared vision for a healthier world.


Shantanu Kumar Singh
Executive Director & Chief Financial Officer
Taj Pharma Group